GFB-024 is under clinical development by Goldfinch Bio and currently in Phase I for Diabetic Nephropathy. According to GlobalData, Phase I drugs for Diabetic Nephropathy have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GFB-024’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GFB-024 overview

GFB-024 is under development for the treatment of diabetic nephropathy (DN) and obesity-related focal segmental glomerulosclerosis (FSGS). It is a injectable monoclonal antibody. It acts by targeting cannabinoid receptor 1.

Goldfinch Bio overview

Goldfinch Bio, formerly Goldfinch Biopharma, is the US-based biotechnology company that develops and discovers therapies to treat chronic kidney disease. It holds a comprehensive patient registry, Kidney Genome Atlas, used for the investigation of kidney disease’s mechanisms.

For a complete picture of GFB-024’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.